NCT07541677Completed
Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%. In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups. The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments. Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 160 (actual)
- First submitted
- 11 Aug 2025
- Start date
- 26 May 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Singapore General Hospital
- Diseases
- Obesity
- NCT number
- NCT07541677
What you commit to
- Study type: Observational
- Participants enrolled: 160
- From 26 May 2025 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)
Other illness
- history of bariatric procedures or surgeries
Other
- unable to undergo the physical function tests (handgrip strength testing and chair-stand tests)
- pregnant women
Who the study is looking for
- body mass index ≥ 27.5kg/m2
- able to provide informed consent.
Age in the registry: 21 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Singapore General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.